SCNX Scienture Holdings Inc.

$SCNX BIG Market Opportunity: EPANED from Azurity Pharma (~$43M peak) validated the demand for liquid antihypertensives, but Arbli™ (Losartan) targets a 24x larger patient base with a modern, FDA-approved ARB formulation. Operational Advantages: Arbli™ eliminates cold-chain logistics with 24-month room-temperature stability, features a taste-masked peppermint flavor for better compliance, and replaces error-prone compounding in hospitals. Long-Term Exclusivity: Backed by robust US patents securing exclusivity through October 2041, Arbli™ provides a fully protected, long-term runway for high-margin growth.

$SCNX *REZENOPY™ selling commercially at 2000 clinics currently *Arbli selling commercially as of last week to the formularies of three U.S. pediatric academic medical centers and hospitals- high margins, gaining momentum * $6 mil market cap - Share Count: ~1,642,565 shares

$SCNX Possible PR on Tuesday pre market with a pontial of huge volume and explosive price movement. If true, this is a last chance to buy today. GLTA.

$SCNX RSI at 8 - this low volume premartket dip is impatient kids who bid dumped, this is the sort of trading that always loses money

$SCNX I know they are splitting on Monday, and I know the company is dumping shares, they all do. But this is a $6 mil market cap and thats a very good PR, revenues and sales are exploding. I'm buying.

$SCNX Don't forget, we're still facing the dilemma of only being above $1 for 5 consecutive trading days by the October 12th compliance deadline, instead of the requisite 10 consecutive trading days.

$SCNX If SCNX can keep OpEx flat or declining while revenues scale at this pace, the operating leverage will drive them into profitability much faster than expected. With 90%+ gross margins, capped expenses mean almost every new dollar drops straight to the bottom line.

$SCNX SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

$SCNX Monday 10/12 is our compliance deadline. Hopefully there aren't any issues since we will only have been above $1.0 for 5 days.

$SCNX is the market cap really 4,8 million as stated on Stocktwits? I should save some more and buy the company lol

$SCNX The only green in my entire portfolio/watchlist everything else got absolutely slaughtered today

$SCNX Targets Profitability In 2027 President and Co-CEO Narasimhan Mani said the company expects its expanding product portfolio to support further revenue growth through the remainder of 2026 and into 2027. He added that Scienture aims to use its historically high gross margins to improve operating leverage as sales increase, supporting its goal of achieving profitability in 2027.

$SCNX prelim Q3 rev $1.22M (up 256%} , market cap $6.4M, 1.3M public float, 1.64M TSO and 22% owned by insiders 🧐🤔

$SCNX Hoping for a delayed reaction. I’ll wait. Do not come across too many or any tiny small float drug makers that are selling their product at a 256% increase. 

SCNX < $5 - BZ: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability 4.50 break and vol could be fun , 1m floater $SCNX

$SCNX I had some luck with this one in the past. Jumping in for 20k share starter at .14. Last time I sold way too early, even though I doubled my money. I’ll be happy with .21 this time around. Not delusional though. Definitely could lose the whole 2800 investment as well.

$SCNX Arbli™ addresses a large and established U.S. losartan market representing approximately $219 million in sales and approximately 72 million prescriptions annually (IQVIA MAT Apr 2026). By eliminating the variability and inconvenience associated with pharmacy compounding, Scienture believes that Arbli™ provides healthcare professionals with a consistent, convenient and scalable ready-to-use treatment option.

$SCNX With this type of revenue SCNX will barely be able to cover the CEO's salary and benefits.

$SCNX I don’t see any problem with this story a tiny drug company in Austin Texas increasing revenue 256% on the sale of their FDA approved drug and predicting profitability in 2027, with other drugs in the pipeline at a price target on their head of $38 , combine that with a super low float just over 1 million shares. I’m in 

$SCNX Recent RS, stabilized on $3.5-3.7 all week. Dilution is real but so had others and they did pumped hard. Watching for a move on volume and I'm in.